Objective:To investigate the efficacy and toxicity of radiotherapy alone,concurrent radiochemotherapy and radiotherapy combined with adjuvant chemotherapy for patients with cervical carcinoma.Methods:Total of 127 patients with cervical cancer receiving radiotherapy in the First Affiliated Hospital of Soochow University between October 2008 and October 2013 were enrolled into this study and divided into three groups:radiotherapy alone group (n =45),radiotherapy with concurrent cisplatin chemotherapy group (n =58) and radiotherapy combined with adjuvant chemotherapy (paclitaxel plus carboplatin) group (n =24).All patients in the three treatment groups received radical radiotherapy including pelvic external radiotherapy and 192Ir brachytherapy.The efficacy,toxicities and survival of three groups were observed.Results:All patients finished treatment.The median follow-up time was 41 months.The rates of complete response of radiotherapy alone group,radiotherapy with concurrent cisplatin chemotherapy group and radiotherapy combined with adjuvant chemotherapy group were 53.3％ (24/45),77.6％ (45/58) and 62.5％ (1 5/24),respectively (P =0.496);the 2-year overall survival rates of these three treatment groups were 66.2％,85.4％ and 74.9％,respectively (P ＜ 0.05);the 3-year overall survival rates were 64.2％,82.4％ and 74.9％,respectively (P ＜ 0.05);the 5-year overall survival rates were 54.8％,78.1％ and 74.9％,respectively (P ＜ 0.05);the 2-year progression-free survival rates were 57.9％,87.2％ and 69.3％,respectively (P ＜ 0.05);the 3-year progression-free survival rates were 56.1％,83.8％ and 69.3％,respectively (P ＜ 0.05).The toxicities were mainly in grades 1-2.There were no significant differences in the rates of leucopenia,thrombocytopenia,nausea and vomiting and bladder injury among the three treatment groups (all P ＞ 0.05).Conclusion:The efficacy of radiotherapy with concurrent cisplatin chemotherapy regimen for patients with cervical cancer is better than radiotherapy alone or radiotherapy combined with adjuvant chemotherapy.This concurrent radiochemotherapy regimen can significantly improve the overall survival and progression-free survival of patients with cervical cancer,but the rates of side effects may be increased.For the cervical cancer patients who can not tolerate concurrent radiochemotherapy,the adjuvant chemotherapy can achieve better benefit in survival rather than radiotherapy alone.

Objective The purpose of the study was to observe and analysis the actual dosage of patients with breast cancer using metal oxide semiconductor field effect transistor (MOSFET) detector.Methods First, Phantom measurements were performed to investigate dose distribution in the area of the junction in a half-field matching method and the influence of factors related to the accelerator. In vivo dose measurements were performed for patients with breast cancer to investigate the skin dose and the junction of supraclavicular-axillary field and tangential field in 6 MV X-ray beams. Results Phantom measurements showed that the relative deviation in the junction were within + 3％, and the dose distributions in the junction area depended on the matching field direction (x or y). In vivo measurement of tangential region for patients showed that, the maximum dose deviation between measurement and calculation was -30. 39％,the minimum deviation was - 18. 85％, the average dose deviation was -24. 76％. The dose deviation of tangential fields for patients with breast-conserving surgery was larger than that patients with radical surgery (t =2. 40 ,P＜0. 05), while dose deviation of supraclavicular-axillary fields was not significantly different. The average values of 15 fraction in the junction area showed more stable than one individual measurement.Conclusions It is important to real-time, in vivo measurement of radiation dose during radiotherapy in patients with breast cancer, and change treatment plan in time, to ensure the accuracy of target dose.

In order to observe impact of PET/CT on precise and accurate radiotherapy (PAR) planning of patients with non-small cell lung cancer (NSCLC),21 patients with NSCLC had CT and FDG-hybrid PET examinations prospectively in radiation treatment position.Five radiation oncologists delineated independently the GTV including positive lymph nodes of 21 lung cancer patients on CT.The same observers delineated the GTV of the 21 patients on matched PET/CT scans.The size of GTV and coefficient of variation were used to assess inter-observer variability.The results show that all patients' GTVCT differed from their GTVPET/CT,and the variability in the contouring of GTVCT among different physicians was statistically significant (F=9.25,P0.001),but less significant in the contouring of GTVPET/CT.The mean coefficient of variation for GTV based on PET/CT was significantly smaller (t=-7.46,P0.001) than that for CT data only.It van be concluded that PET/CT may have notable impact on clinical staging of NSCLC and on its PAR planning,and will result in a reduction in this variation of the contouring of GTVs among different radiation oncologists.